Immunotherapeutic strategy | Adjuvant/interventions | Indications | Phase | Trial ID |
---|---|---|---|---|
NY-ESO-1 protein vaccine | CpG 7909 | Advanced prostate cancer | 1 | NCT00292045 |
Cholesteryl pullulan(CHP) + CHP HER2 + OK-432 | Esophageal cancer, lung cancer, stomach cancer, breast cancer, ovarian cancer | 1 | NCT00291473 | |
Glucopyranosyl lipid adjuvant stable emulsion (GLA-SE) | Melanoma, ovarian cancer, sarcoma non-small cell lung cancer, breast cancer | 1 | NCT02015416 | |
Recombinant Fowl-Pox virus vector | Fallopian tube cancer, ovarian cancer, peritoneal cavity cancer | 2 | NCT00112957 | |
Recombinant canarypox virus vector (ALVAC) 2 + TRIad of Co-stimulatory molecules B7-1, ICAM- and LFA-3. | Fallopian tube cancer, ovarian cancer, peritoneal cavity cancer | 1 | NCT00803569 | |
ISCOMATRIX | Melanoma | 2 | NCT00518206 | |
Imiquimod | Malignant melanoma | 1 | NCT00142454 | |
NY-ESO-1 peptide vaccine | Montanide, montanide + carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-l-lysine (Poly-ICLC) | Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer | 1 | NCT00616941 |
CpG 7909 + montanide ISA-51 | Stage III/IV;resected Stage II, III, or IV non-small cell lung cancer or esophageal cancer | 1 | NCT00199836 | |
None | Prostate cancer | 1 | NCT00616291 | |
CpG 7909, CpG 7909 + montanide ISA 720 | All NY-ESO-1 expressing tumors | 1 | NCT00819806 | |
BCG vaccine, sargramostim | Bladder cancer | 1 | NCT00070070 | |
Resiquimod | Melanoma | 1 | NCT00470379 | |
NY-ESO-1 TCR | Palliative radiation therapy | Sarcoma | 1 | NCT02319824 |
NY-ESO-1 specific monoclonal antibody | Resiquimod and/or carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-l-lysine (poly-ICLC) | Advanced malignancies | 1 and 2 | NCT00948961 |